文献速递淋巴瘤造血干细胞移植与细胞治疗

接受利妥昔单抗治疗的淋巴瘤患者在COVID-19疫苗接种后产生强CD8 T细胞应答

Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
PubMed 文献 · Br J Haematol · 2022-03-21

研究纳入110例接受抗CD20单抗治疗的淋巴瘤患者和16名年龄匹配的健康献血者,接种两剂COVID-19疫苗后3-6周,仅7/110例患者检出针对SARS-CoV-2 Spike蛋白受体结合域的抗体,但患者CD8 T细胞应答频率(20/29,69%)和幅度与对照(12/16,75%)相似。结论认为尽管体液免疫缺失,患者仍可能从现有COVID-19疫苗中获益。

要点

  • 抗CD20治疗的淋巴瘤患者接种两剂疫苗后仅7/110例检出Spike受体结合域抗体。
  • 患者CD8 T细胞应答频率为20/29(69%),对照组为12/16(75%)。
  • 两组CD8 T细胞应答中位幅度相似,部分最强应答见于患者。

核心结论

  • 尽管完全接种SARS-CoV-2疫苗的抗CD20治疗淋巴瘤患者缺乏体液免疫应答,其CD8 T细胞应答频率和幅度与对照相似。
  • 接受B细胞清除治疗的淋巴瘤患者可能从当前COVID-19疫苗中获益。
  • 开发旨在诱导针对非Spike表位T细胞应答的疫苗可能提供更好的保护。

研究设计与样本

  • 研究纳入过去9个月内接受抗CD20单抗单药或联合化疗或其他抗肿瘤药物治疗的淋巴瘤患者,以及年龄匹配的健康献血者。
  • 检测两次疫苗接种后3-6周针对SARS-CoV-2 Spike蛋白受体结合域的抗体。
  • 通过肽-HLA多聚体分析检测外周血CD8 T细胞针对流行HLA I类SARS-CoV-2表位的应答。

主要发现

  • 110例患者中7例在第二剂疫苗接种后3-6周检出针对SARS-CoV-2 Spike蛋白受体结合域的抗体。
  • 患者中20/29例(69%)观察到强CD8 T细胞应答,对照组为12/16例(75%)。
  • 两组CD8 T细胞应答中位幅度相似,部分最强应答见于患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3-6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Riise J, Meyer S, Blaas I, et al. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol. 2022. PMID: 35254660. doi:10.1111/bjh.18149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。